6-73641810-T-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_012434.5(SLC17A5):āc.406A>Gā(p.Lys136Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000874 in 1,614,010 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ).
Frequency
Genomes: š 0.000072 ( 0 hom., cov: 32)
Exomes š: 0.000089 ( 0 hom. )
Consequence
SLC17A5
NM_012434.5 missense
NM_012434.5 missense
Scores
11
6
2
Clinical Significance
Conservation
PhyloP100: 7.48
Genes affected
SLC17A5 (HGNC:10933): (solute carrier family 17 member 5) This gene encodes a membrane transporter that exports free sialic acids that have been cleaved off of cell surface lipids and proteins from lysosomes. Mutations in this gene cause sialic acid storage diseases, including infantile sialic acid storage disorder and and Salla disease, an adult form. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.938
PP5
Variant 6-73641810-T-C is Pathogenic according to our data. Variant chr6-73641810-T-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 21493.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr6-73641810-T-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC17A5 | NM_012434.5 | c.406A>G | p.Lys136Glu | missense_variant | 3/11 | ENST00000355773.6 | NP_036566.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC17A5 | ENST00000355773.6 | c.406A>G | p.Lys136Glu | missense_variant | 3/11 | 1 | NM_012434.5 | ENSP00000348019.5 | ||
SLC17A5 | ENST00000481996.1 | n.172A>G | non_coding_transcript_exon_variant | 2/5 | 4 |
Frequencies
GnomAD3 genomes AF: 0.0000724 AC: 11AN: 152012Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
11
AN:
152012
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000318 AC: 8AN: 251472Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135906
GnomAD3 exomes
AF:
AC:
8
AN:
251472
Hom.:
AF XY:
AC XY:
5
AN XY:
135906
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000889 AC: 130AN: 1461880Hom.: 0 Cov.: 31 AF XY: 0.0000990 AC XY: 72AN XY: 727242
GnomAD4 exome
AF:
AC:
130
AN:
1461880
Hom.:
Cov.:
31
AF XY:
AC XY:
72
AN XY:
727242
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152130Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74352
GnomAD4 genome
AF:
AC:
11
AN:
152130
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74352
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
3
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:14Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Salla disease Pathogenic:8
Pathogenic, criteria provided, single submitter | clinical testing | New York Genome Center | Aug 26, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 136 of the SLC17A5 protein (p.Lys136Glu). This variant is present in population databases (rs80338795, gnomAD 0.007%). This missense change has been observed in individuals with SLC17A5-related conditions (PMID: 10947946, 16170568, 19557856). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 21493). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC17A5 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects SLC17A5 function (PMID: 15510212, 15516337, 21781115). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Mar 30, 2014 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 2005 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 23, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Sep 05, 2021 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City | Sep 26, 2019 | - - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Oct 06, 2023 | PP1_strong, PP3, PM2_moderate, PM3_very_strong, PS3, PS4_moderate - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 12, 2023 | Published functional studies demonstrate approximately 10% residual enzyme activity compared to wild-type, similar to the R39C variant, the common variant associated with Salla disease (PMID: 15516337); Another published functional study found that K136E mutant sialin protein did not transport aspartate and glutamate; however, H+/sialic acid co-transport activity was 50% of the wild-type protein, which was also similar to the results seen for the R39C variant (PMID: 21781115); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 10947946, 19557856, 15510212, 33862140, 16170568, 32371413, 32608236, 36662855, 37713976, 37272184, 21781115, 15516337) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Mar 01, 2023 | SLC17A5: PM3:Strong, PS4, PM2, PS3:Supporting - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 08, 2019 | - - |
Sialic acid storage disease, severe infantile type;C1096903:Salla disease Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Institute for Genomic Medicine (IGM) Clinical Laboratory, Nationwide Children's Hospital | Feb 20, 2018 | [ACMG/AMP: PS3, PM2, PS4_Moderate, PP3, PP5] This alteration is supported by well-established in vitro or in vivo functional studies to have a damaging effect on protein function or splicing [PS3], is absent from or rarely observed in large-scale population databases [PM2], has previously been observed in multiple unrelated patients with the same phenotype [PS4_Moderate], is predicted to be damaging by multiple functional prediction tools [PP3], was reported as a pathogenic/likely pathogenic alteration by a reputable source (ClinVar or other correspondence from a clinical testing laboratory) [PP5]. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Sialic acid storage disease, severe infantile type Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D
M_CAP
Benign
D
MetaRNN
Pathogenic
D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
H
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D
REVEL
Pathogenic
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
D
Vest4
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at